---
id: chai-discovery
slug: chai-discovery
entity_type: commercial
status: operational
data_completeness: high
last_researched: 2025-01-27
researcher: AI Assistant
version: 2.1
name: Chai Discovery
description: AI-powered molecular design and drug discovery company specializing in de novo antibody design. Achieved breakthrough ~20% success rate in fully de novo antibody design with Chai-2 model, representing 100-fold improvement over traditional methods.
mission: To transform biology from a descriptive science into an engineering discipline by using advanced AI models to predict and reprogram interactions between biochemical molecules. Chai Discovery aims to accelerate the development of vital therapeutics by enabling de novo design of molecules with desired properties, dramatically improving success rates compared to traditional methods.
entity_data:
  focus: AI-powered molecular design and drug discovery. Specializes in using advanced AI models to predict and reprogram interactions between biochemical molecules to accelerate development of new therapeutics
  status: operational
  founded: 2024
  website: "https://www.chaidiscovery.com"
  industry: Biotechnology
  employees:
  as_of: 2025
  current: Not disclosed
  legal_name: Chai Discovery
  headquarters:
  city: San Francisco
  state: California
  address: 55 Pacific Avenue, San Francisco, CA 94111
  country: USA
taxonomy:
  geography: USA
  ai_approach:
  - Generative AI
  ai_technology:
  - Generative AI
  - Protein LMs
  primary_focus:
  - AI-Driven Drug Discovery
  - Protein Design & Engineering
  aging_approach:
  - Molecule Design
  - Therapeutic Development
  target_biology:
  - General Aging/Longevity
  ai_architecture:
  - Protein LMs
  ai_specialization: []
  development_stage: operational
  organization_type: commercial
  organization_subtype: operational
  therapeutic_modality:
  - Therapeutic Proteins
organizations:
  -
    name: Chai Discovery
    role: primary
    org_type: company
    legal_name: Chai Discovery
    founded: 2024
    website: "https://www.chaidiscovery.com"
    status: operational
    role_description: Primary organization - developer of Chai-2 and Chai Platform
    contribution_description: Developed AI foundation models for de novo antibody design, raised $225M+ in funding, achieved unicorn status
products:
  -
    name: Chai Platform
    type: platform
    status: In Development
    development_stage: Research / Preclinical
  -
    name: Chai-2
    type: ai_model
    status: Available
    development_stage: Operational
links:
  -
    url: "https://internal-reference/chai-discovery/zero-shot-biologics-design"
    type: reference
    title: Zero-Shot Biologics Design
  -
    url: "https://internal-reference/chai-discovery/foundation-models-protein-design"
    type: reference
    title: Foundation Models for Protein Design
  -
    url: "https://internal-reference/chai-discovery/de-novo-antibody-design"
    type: reference
    title: De Novo Antibody Design with AI - Chai Discovery Breakthrough
  -
    url: "https://www.biopharmatrend.com/news/chai-discovery-raises-70m-to-expand-zero-shot-biologics-design-ai-platform-1331/"
    type: news_article
    title: Chai Discovery Raises $70M to Expand Zero-Shot Biologics Design AI Platform
  -
    url: "https://www.fiercebiotech.com/biotech/chai-infuses-ai-drug-discovery-efforts-130m-series-b"
    type: news_article
    title: AI Drug Discovery Startup Chai Discovery Raises $130M Series B
  -
    url: "https://observer.com/2025/12/chai-discovery-latest-ai-unicorn/"
    type: news_article
    title: "Chai Discovery: Latest AI Unicorn"
  -
    url: "https://www.investing.com/news/company-news/chai-discovery-raises-130-million-reaches-13-billion-valuation-93CH-4408011"
    type: news_article
    title: Chai Discovery Raises $130 Million, Reaches $1.3 Billion Valuation
  -
    url: "https://www.chaidiscovery.com/product"
    type: website
    title: Chai Discovery Product - De Novo Protein Design
  -
    url: "https://www.businesswire.com/news/home/20251214931432/en/Chai-Discovery-Announces-%24130-Million-Series-B-To-Transform-Molecular-Discovery"
    type: press_release
    title: Chai Discovery Announces $130 Million Series B To Transform Molecular Discovery
  -
    url: "https://www.businesswire.com/news/home/20250630307418/en/Chai-Discovery-Unveils-Chai-2-Breakthrough-Achieving-Fully-De-Novo-Antibody-Design-With-AI"
    type: press_release
    title: "Chai Discovery Unveils Chai-2 Breakthrough: Achieving Fully De Novo Antibody Design With AI"
  -
    url: "https://www.businesswire.com/news/home/20250806670137/en/Chai-Discovery-Announces-%2470-million-Series-A-To-Transform-Molecular-Design"
    type: press_release
    title: Chai Discovery Announces $70 Million Series A To Transform Molecular Design
---

# Chai Discovery

## Description

AI-powered molecular design and drug discovery company specializing in de novo antibody design. Achieved breakthrough ~20% success rate in fully de novo antibody design with Chai-2 model, representing 100-fold improvement over traditional methods.

## Mission

To transform biology from a descriptive science into an engineering discipline by using advanced AI models to predict and reprogram interactions between biochemical molecules. Chai Discovery aims to accelerate the development of vital therapeutics by enabling de novo design of molecules with desired properties, dramatically improving success rates compared to traditional methods.

## Company Information

**Legal Name**: Chai Discovery
**Founded**: 2024
**Industry**: Biotechnology
**Employees**: {"as_of":"2025","current":"Not disclosed"}
**Focus**: AI-powered molecular design and drug discovery. Specializes in using advanced AI models to predict and reprogram interactions between biochemical molecules to accelerate development of new therapeutics
**Website**: https://www.chaidiscovery.com

## Scientific Background

```yaml
biological_context:
  challenge: Designing sequences that simultaneously meet all these requirements is extremely difficult, requiring exploration of vast sequence space
  antibody_structure: Antibodies are Y-shaped proteins with variable regions that bind to specific targets (antigens). The variable region sequence determines binding specificity and affinity.
  design_requirements: "Effective therapeutic antibodies must have: (1) High affinity for target, (2) High specificity (minimal off-target binding), (3) Favorable pharmacokinetic properties, (4) Low immunogenicity"
ai_approach_advantage:
  speed_improvement: AI design can generate candidates in hours/days rather than months/years
  pattern_recognition: Foundation models learn patterns from large-scale antibody data, enabling prediction of sequences likely to have desired properties
  zero_shot_capability: Ability to design for new targets without target-specific training data dramatically expands applicability
  sequence_space_exploration: AI models can explore the vast antibody sequence space computationally, identifying promising candidates before laboratory testing
impact_on_drug_discovery:
  acceleration: 100-fold improvement in success rate dramatically accelerates antibody development timelines
  ai_enablement: AI-driven de novo design enables targeting of previously undruggable targets by designing antibodies from scratch rather than relying on existing libraries
  undruggable_targets: "Many disease targets are considered 'undruggable' with small molecules. Antibodies can target these, but traditional design methods often fail."
antibody_design_challenge:
  time_cost: Traditional antibody development can take months to years, with multiple rounds of optimization and screening.
  bottleneck: The vast sequence space of possible antibodies (10^12+ potential sequences) makes exhaustive experimental screening impossible. Traditional methods can only explore a tiny fraction of this space.
  traditional_limitations: Traditional antibody design methods rely on existing antibody libraries, phage display, or hybridoma technology. These methods have extremely low success rates (<0.1%) and require extensive experimental screening and optimization.
```

## Lessons Learned

### Achievements

- Developed Chai-2 achieving ~20% success rate in de novo antibody design (100-fold improvement)
- Raised $225M+ in total funding across seed, Series A, and Series B
- Reached $1.3B valuation (unicorn status) in December 2025
- Attracted high-profile investors including OpenAI, Thrive Capital, Menlo Ventures, Oak HC/FT, General Catalyst
- Recruited Mikael Dolsten (former CSO of Pfizer) to board of directors
- Demonstrated ability to design full-length monoclonal antibodies with high specificity and favorable therapeutic profiles
- Enabled zero-shot biologics design without extensive laboratory testing

### Challenges

- Achieving high success rates in de novo antibody design (traditionally <0.1%)
- Designing antibodies with desired properties (affinity, specificity, pharmacokinetics) from scratch
- Scaling AI models for diverse molecular design applications
- Validating AI-designed molecules in laboratory and clinical settings
- Balancing model complexity with computational efficiency
- Ensuring designed antibodies meet multiple simultaneous requirements (affinity, specificity, developability)

### Impact on Field

Chai Discovery represents a breakthrough in AI-powered drug discovery, achieving a 100-fold improvement in de novo antibody design success rates. The Chai-2 model's ability to design functional antibodies from scratch with only target antigen and epitope information eliminates the need for extensive laboratory optimization, dramatically accelerating therapeutic development. For longevity research, this capability enables rapid design of antibodies targeting aging-related pathways and age-related diseases. The company's approach of transforming biology from a descriptive science into an engineering discipline has significant implications for the entire drug discovery field. With $1.3B valuation and strong investor backing (including OpenAI), Chai Discovery is well-positioned to accelerate the development of novel therapeutics for aging and other conditions.

## Organizations

### Chai Discovery
**Role in Project**: primary
**Role Description**: Primary organization - developer of Chai-2 and Chai Platform
**Contribution**: Developed AI foundation models for de novo antibody design, raised $225M+ in funding, achieved unicorn status
**Organization Type**: company
**Status**: operational
**Founded**: 2024
**Website**: https://www.chaidiscovery.com
**Description**: AI-powered molecular design and drug discovery company specializing in de novo antibody design. Achieved breakthrough ~20% success rate in fully de novo antibody design with Chai-2 model, representing 100-fold improvement over traditional methods.
**Focus**: AI-powered molecular design and drug discovery. Specializes in using advanced AI models to predict and reprogram interactions between biochemical molecules to accelerate development of new therapeutics

## Locations

### Chai Discovery Headquarters
**Type**: headquarters
**Address**: 55 Pacific Avenue, San Francisco, CA 94111
**City**: San Francisco
**State/Region**: California
**Country**: USA
**Organizations**: Chai Discovery

## Products

### Chai Platform
**Alternative Names**: Chai
**Type**: platform
**Status**: In Development
**Development Stage**: Research / Preclinical
**Role in Project**: primary
**Relationship Description**: Platform for de novo protein design and molecular discovery
**Description**: Platform for de novo protein design providing high success rates and ability to work with various antibody formats. Uses advanced AI models to predict and reprogram molecular interactions for accelerating drug discovery.
**Mechanism of Action**: Platform for de novo protein design providing high success rates and ability to work with various antibody formats. Uses advanced AI models to predict and reprogram molecular interactions for accelerating drug discovery.
**Target**: Molecular design and drug discovery
**Pathway**: Therapeutic molecule development
**Capabilities**:
- Predict molecular interactions
- Reprogram biochemical molecule interactions
- De novo protein design
- Work with various antibody formats
**Indications**: [
  {
    "primary": "Molecular design for drug discovery",
    "secondary": [
      "Protein design",
      "Antibody optimization"
    ]
  }
]
**Technical Details**:
```yaml
notes: Platform for transforming molecular discovery and design
architecture: AI platform for molecular design
regulatory_status: Research platform
```

### Chai-2
**Type**: ai_model
**Status**: Available
**Development Stage**: Operational
**Role in Project**: primary
**Relationship Description**: Primary AI model achieving breakthrough in de novo antibody design with ~20% success rate
**Description**: Second-generation AI model capable of fully de novo antibody design from scratch. The model can design new antibodies using only information about the target antigen and epitope, without the need for extensive laboratory testing or optimization. Achieves approximately 20% success rate in creating functional antibodies, representing a 100-fold improvement over existing methods (which have <0.1% success rate).
**Mechanism of Action**: Second-generation AI model capable of fully de novo antibody design from scratch. The model can design new antibodies using only information about the target antigen and epitope, without the need for extensive laboratory testing or optimization. Achieves approximately 20% success rate in creating functional antibodies, representing a 100-fold improvement over existing methods (which have <0.1% success rate).
**Target**: Antibody design
**Pathway**: Therapeutic antibody development
**Capabilities**:
- Fully de novo antibody design from scratch
- Design full-length monoclonal antibodies
- High specificity and favorable therapeutic profiles
- High affinity, specificity, and good pharmacokinetic properties
- Zero-shot design (no experimental optimization needed)
- Design for previously undruggable targets
**Indications**: [
  {
    "primary": "De novo antibody design for difficult-to-treat diseases",
    "secondary": [
      "Therapeutic antibodies",
      "Targeting previously undruggable targets"
    ]
  }
]
**Technical Details**:
```yaml
notes: Unveiled in June 2025, achieving fully de novo antibody design with AI. Represents breakthrough in zero-shot biologics design.
output:
  type: Full-length monoclonal antibodies with high specificity
  properties:
  - Designed antibody sequences
  - Predicted binding properties
  - Therapeutic profiles
deployment:
  usage: Researchers and drug developers can input target information and receive designed antibody sequences
  platform: Web-based platform or API access
launch_date: 2025-06
architecture:
  type: AI Foundation Model (likely transformer-based or diffusion-based architecture)
  description: Foundation model trained on large-scale protein/antibody sequence data. Architecture details not fully disclosed, but likely uses transformer or diffusion architecture similar to protein language models. Designed for zero-shot de novo antibody generation.
  model_family: Foundation model for biologics design
  training_approach: Self-supervised or supervised learning on large antibody/protein sequence datasets
success_rate:
  value: ~20%
  comparison: <0.1% for traditional methods
  definition: Percentage of designed antibodies that demonstrate functional binding and desired properties in laboratory validation
  improvement: 100-fold improvement over existing methods
  validation_method: Laboratory testing of designed antibodies for binding affinity, specificity, and functional properties
training_data:
  scale: Large-scale dataset (exact size not publicly disclosed)
  data_types:
  - Antibody sequences
  - Protein structures
  - Protein-protein interaction data
  - Antigen-epitope binding data
  description: Trained on large-scale datasets of antibody sequences, protein structures, and protein-protein interactions
regulatory_status: Research platform / Drug discovery tool
input_requirements:
  minimal_input: Only target antigen and epitope information needed
  no_required_data:
  - No need for existing antibody libraries
  - No need for extensive experimental screening
  - No need for iterative optimization cycles
```

## Key People

### Mikael Dolsten
**Participation Type**: leadership
**Role in Project**: Board Member
**Participation Period**: 2025-present
**Contribution**: Board member providing strategic guidance and pharmaceutical industry expertise
**Expertise**: Pharmaceutical R&D, drug development
**Biography**: Former Chief Scientific Officer of Pfizer

### Jacques Boitreau
**Participation Type**: founder
**Role in Project**: Co-founder
**Participation Period**: 2024-present
**Contribution**: Co-founded Chai Discovery, contributes to AI research and development
**Expertise**: AI research, machine learning
**Biography**: AI researcher

### Matthew McPartlon
**Participation Type**: founder
**Role in Project**: Co-founder
**Participation Period**: 2024-present
**Contribution**: Co-founded Chai Discovery, contributes to AI research and development
**Expertise**: AI research, machine learning
**Biography**: AI researcher

### Jack Dent
**Participation Type**: founder
**Role in Project**: Co-founder
**Participation Period**: 2024-present
**Contribution**: Co-founded Chai Discovery, leads engineering and product development
**Expertise**: Engineering, product development
**Biography**: Former engineering and product team leader at Stripe

### Joshua Meier
**Participation Type**: founder
**Role in Project**: CEO, Co-founder
**Participation Period**: 2024-present
**Contribution**: Founded Chai Discovery, leads company strategy and AI development
**Expertise**: AI/ML, protein design, drug discovery
**Biography**: Previously Chief AI Officer at Absci, researcher at OpenAI and Facebook AI

## Links

### [Zero-Shot Biologics Design](https://internal-reference/chai-discovery/zero-shot-biologics-design)
**Type**: reference
**Relevance**: tertiary
**Category**: reference
**Description**: Concept of zero-shot design in biologics, enabling design without target-specific training data

### [Foundation Models for Protein Design](https://internal-reference/chai-discovery/foundation-models-protein-design)
**Type**: reference
**Relevance**: tertiary
**Category**: reference
**Description**: Technical context on foundation models for protein and antibody design

### [De Novo Antibody Design with AI - Chai Discovery Breakthrough](https://internal-reference/chai-discovery/de-novo-antibody-design)
**Type**: reference
**Relevance**: tertiary
**Category**: reference
**Description**: Background on de novo antibody design challenges and AI approaches

### [Chai Discovery Raises $70M to Expand Zero-Shot Biologics Design AI Platform](https://www.biopharmatrend.com/news/chai-discovery-raises-70m-to-expand-zero-shot-biologics-design-ai-platform-1331/)
**Type**: news_article
**Relevance**: secondary
**Category**: source
**Publication Date**: 2025-08-01
**Description**: Biopharma Trend article about Series A funding and platform expansion

### [AI Drug Discovery Startup Chai Discovery Raises $130M Series B](https://www.fiercebiotech.com/biotech/chai-infuses-ai-drug-discovery-efforts-130m-series-b)
**Type**: news_article
**Relevance**: secondary
**Category**: source
**Publication Date**: 2025-12-01
**Description**: Fierce Biotech article about Series B funding round

### [Chai Discovery: Latest AI Unicorn](https://observer.com/2025/12/chai-discovery-latest-ai-unicorn/)
**Type**: news_article
**Relevance**: secondary
**Category**: source
**Publication Date**: 2025-12-01
**Description**: News article about Chai Discovery reaching unicorn status

### [Chai Discovery Raises $130 Million, Reaches $1.3 Billion Valuation](https://www.investing.com/news/company-news/chai-discovery-raises-130-million-reaches-13-billion-valuation-93CH-4408011)
**Type**: news_article
**Relevance**: secondary
**Category**: source
**Publication Date**: 2025-12-01
**Description**: News article about Series B funding and unicorn status

### [Chai Discovery Product - De Novo Protein Design](https://www.chaidiscovery.com/product)
**Type**: website
**Relevance**: primary
**Category**: source
**Description**: Product page describing de novo protein design platform

### [Chai Discovery Announces $130 Million Series B To Transform Molecular Discovery](https://www.businesswire.com/news/home/20251214931432/en/Chai-Discovery-Announces-%24130-Million-Series-B-To-Transform-Molecular-Discovery)
**Type**: press_release
**Relevance**: primary
**Category**: source
**Publication Date**: 2025-12-14
**Description**: Press release announcing $130M Series B funding and $1.3B valuation

### [Chai Discovery Unveils Chai-2 Breakthrough: Achieving Fully De Novo Antibody Design With AI](https://www.businesswire.com/news/home/20250630307418/en/Chai-Discovery-Unveils-Chai-2-Breakthrough-Achieving-Fully-De-Novo-Antibody-Design-With-AI)
**Type**: press_release
**Relevance**: primary
**Category**: source
**Publication Date**: 2025-06-30
**Description**: Press release announcing Chai-2 model launch

### [Chai Discovery Announces $70 Million Series A To Transform Molecular Design](https://www.businesswire.com/news/home/20250806670137/en/Chai-Discovery-Announces-%2470-million-Series-A-To-Transform-Molecular-Design)
**Type**: press_release
**Relevance**: primary
**Category**: source
**Publication Date**: 2025-08-06
**Description**: Press release announcing $70M Series A funding round

## Financials

### funding
**Amount**: $130 million USD
**Amount (Numeric)**: 130000000
**Funding Date**: 2025-12-01
**Funding Type**: Series B
**Description**: Series B funding to transform molecular discovery. Funds will be used to further develop Chai platform, expand commercialization, and accelerate R&D
**Details**:
```yaml
type: Series B
year: 2025
month: December
valuation: $1.3 billion
lead_investors:
  - Oak HC/FT
  - General Catalyst
unicorn_status: true
participating_investors:
  - Thrive Capital
  - OpenAI
  - Dimension
  - Menlo Ventures
```

### funding
**Amount**: $70 million USD
**Amount (Numeric)**: 70000000
**Funding Date**: 2025-08-01
**Funding Type**: Series A
**Description**: Series A funding to transform molecular design and expand zero-shot biologics design AI platform
**Details**:
```yaml
type: Series A
year: 2025
month: August
valuation: $550 million
lead_investors:
  - Menlo Ventures (Anthology Fund)
participating_investors:
  - Yosemite
  - DST Global Partners
  - SV Angel
  - Avenir
  - DCVC
```

### funding
**Amount**: $30 million USD
**Amount (Numeric)**: 30000000
**Funding Date**: 2024-09-01
**Funding Type**: Seed
**Description**: Seed funding round led by Thrive Capital and OpenAI
**Details**:
```yaml
type: Seed
year: 2024
month: September
valuation: $150 million
lead_investors:
  - Thrive Capital
  - OpenAI
```

## Events

### Company Founded
**Date**: 2024-01-01
**Type**: foundation
**Description**: Chai Discovery founded in San Francisco, California by Joshua Meier, Jack Dent, Matthew McPartlon, and Jacques Boitreau

### Seed Funding
**Date**: 2024-09-01
**Type**: funding
**Description**: Raised $30M in seed funding led by Thrive Capital and OpenAI, valuing company at $150M
**Details**:
```yaml
amount: $30 million
investors:
  - Thrive Capital
  - OpenAI
valuation: $150 million
```

### Board Appointment
**Date**: 2025-01-01
**Type**: board_appointment
**Description**: Mikael Dolsten, former Chief Scientific Officer of Pfizer, joined board of directors
**Details**:
```yaml
person: Mikael Dolsten
previous_role: Chief Scientific Officer of Pfizer
```

### Product Launch - Chai-2
**Date**: 2025-06-01
**Type**: launch
**Description**: Unveiled Chai-2, achieving fully de novo antibody design with AI. Model achieves ~20% success rate (100-fold improvement over traditional methods)
**Details**:
```yaml
product: Chai-2
improvement: 100-fold over traditional methods
success_rate: ~20%
```

### Series A Funding
**Date**: 2025-08-01
**Type**: funding
**Description**: Raised $70M in Series A funding led by Menlo Ventures, valuing company at $550M. Funding to transform molecular design and expand zero-shot biologics design platform
**Details**:
```yaml
amount: $70 million
valuation: $550 million
lead_investor: Menlo Ventures (Anthology Fund)
participating_investors:
  - Yosemite
  - DST Global Partners
  - SV Angel
  - Avenir
  - DCVC
```

### Series B Funding & Unicorn Status
**Date**: 2025-12-01
**Type**: funding
**Description**: Raised $130M in Series B funding led by Oak HC/FT and General Catalyst, reaching $1.3B valuation (unicorn status). Total funding reached $225M+
**Details**:
```yaml
amount: $130 million
valuation: $1.3 billion
total_funding: $225 million+
lead_investors:
  - Oak HC/FT
  - General Catalyst
unicorn_status: true
participating_investors:
  - Thrive Capital
  - OpenAI
  - Dimension
  - Menlo Ventures
```
